Combining our result and previous studies, we hypothesized that, for osteosarcoma patients without response to anti-PD1/PDL1 therapy, targeting VTCN1 or HHLA2 was a potentially promising treatment method. This evidence concerns the gene CD274 and osteosarcoma.